Phase 3 Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Therapy Compared with Placebo in Patients with Moderate to Severe Active Ulcerative Colitis (UC) Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

August 22, 2018
https://clinicaltrials.gov/ct2/show/NCT02165215
Gastroenterology Hepatology
Principal Investigator: Nirmal Kaur, MD
uc, UC, ulcerative colitis, IBD,
Open